DE69532996D1 - Peptidanaloge des menschlichen basischen myelinproteins - Google Patents
Peptidanaloge des menschlichen basischen myelinproteinsInfo
- Publication number
- DE69532996D1 DE69532996D1 DE69532996T DE69532996T DE69532996D1 DE 69532996 D1 DE69532996 D1 DE 69532996D1 DE 69532996 T DE69532996 T DE 69532996T DE 69532996 T DE69532996 T DE 69532996T DE 69532996 D1 DE69532996 D1 DE 69532996D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide analogs
- protein
- myeline
- analogs
- human basic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US342408 | 1994-11-18 | ||
US08/342,408 US6329499B1 (en) | 1994-11-18 | 1994-11-18 | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
PCT/US1995/014403 WO1996016086A1 (en) | 1994-11-18 | 1995-11-16 | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69532996D1 true DE69532996D1 (de) | 2004-06-09 |
DE69532996T2 DE69532996T2 (de) | 2005-04-14 |
Family
ID=23341698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69532996T Expired - Fee Related DE69532996T2 (de) | 1994-11-18 | 1995-11-16 | Peptidanaloge des menschlichen basischen myelinproteins |
Country Status (13)
Country | Link |
---|---|
US (2) | US6329499B1 (de) |
EP (2) | EP0792287B1 (de) |
JP (1) | JPH10509172A (de) |
AT (1) | ATE266043T1 (de) |
AU (1) | AU4405896A (de) |
CA (1) | CA2204147A1 (de) |
DE (1) | DE69532996T2 (de) |
DK (1) | DK0792287T3 (de) |
ES (1) | ES2218559T3 (de) |
MX (1) | MX9703643A (de) |
NO (1) | NO972264L (de) |
PT (1) | PT792287E (de) |
WO (1) | WO1996016086A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
IL115766A0 (en) * | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6251396B1 (en) * | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
WO1996016085A1 (en) | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
US5874531A (en) * | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
AU5360796A (en) * | 1995-03-09 | 1996-10-02 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
US6737057B1 (en) | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
CA2201841C (en) * | 1997-04-04 | 2010-01-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US20030191063A1 (en) | 2000-08-21 | 2003-10-09 | Wraith David Cameron | Peptide selection method |
CA2444911A1 (en) * | 2001-05-01 | 2002-11-07 | Andrew Saxon | Fusion molecules and methods for treatment of immune diseases |
US7265208B2 (en) | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
KR20050071565A (ko) | 2002-10-10 | 2005-07-07 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도 |
US7084247B2 (en) * | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
WO2006019982A2 (en) * | 2004-07-15 | 2006-02-23 | Vernalis Plc | Pin1-modulating compounds and methods of use thereof |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
PT2347775T (pt) | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
WO2009002401A2 (en) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
WO2009146456A1 (en) | 2008-05-30 | 2009-12-03 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
AU2010278702C1 (en) * | 2009-07-31 | 2016-07-14 | Forsyth Dental Infirmary For Children | Programming of cells for tolerogenic therapies |
EP2542230A4 (de) | 2010-03-05 | 2013-08-28 | Harvard College | Förderung des anwachsens von skelettmuskel-stammzellen durch gleichzeitige verabreichung von vegf und igf-1 |
WO2011163669A2 (en) | 2010-06-25 | 2011-12-29 | President And Fellows Of Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
DK2624873T3 (da) | 2010-10-06 | 2020-03-02 | Harvard College | Injicerbare, pore-dannende hydrogeler til materiale-baserede celleterapier |
WO2012064697A2 (en) | 2010-11-08 | 2012-05-18 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
EP2701745B1 (de) | 2011-04-28 | 2018-07-11 | President and Fellows of Harvard College | Injizierbare vorgeformte makroskopische 3d-gerüste für minimal invasive verabreichung |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
US9486512B2 (en) | 2011-06-03 | 2016-11-08 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
WO2013158673A1 (en) | 2012-04-16 | 2013-10-24 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
WO2015168379A2 (en) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
CA3012602A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN107708756A (zh) | 2015-04-10 | 2018-02-16 | 哈佛学院院长等 | 免疫细胞捕获装置及其制备和使用方法 |
WO2017136837A1 (en) | 2016-02-06 | 2017-08-10 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
EP3484448A4 (de) | 2016-07-13 | 2020-04-01 | President and Fellows of Harvard College | Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340012C (en) | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
EP0782859A1 (de) | 1990-03-02 | 1997-07-09 | Autoimmune, Inc. | Erhöhung der Verminderungsregulation von Autoimmunkrankheiten durch orale Verabreichung von Autoantigenen |
US5858980A (en) | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
AU674494B2 (en) | 1991-05-31 | 1997-01-02 | Xoma Corporation | T cell receptor peptides as therapeutics for immune-related disease |
US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
CA2053799C (en) | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
JP3434510B2 (ja) | 1992-04-09 | 2003-08-11 | オートイミューン インク | ミエリン塩基性タンパク質のペプチドフラグメントを用いたt‐細胞増殖の抑制 |
JPH06157591A (ja) * | 1992-11-27 | 1994-06-03 | Teijin Ltd | 抗凝固性ペプチド |
US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
EP0720622A1 (de) | 1993-09-22 | 1996-07-10 | The Board Of Trustees Of The Leland Stanford Junior University | Wechselwirkung zwischen t-zellrezeptoren und antigen in autoimmunkrankheiten |
WO1996016085A1 (en) | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
AU5360796A (en) * | 1995-03-09 | 1996-10-02 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
-
1994
- 1994-11-18 US US08/342,408 patent/US6329499B1/en not_active Expired - Fee Related
-
1995
- 1995-11-16 DE DE69532996T patent/DE69532996T2/de not_active Expired - Fee Related
- 1995-11-16 WO PCT/US1995/014403 patent/WO1996016086A1/en active IP Right Grant
- 1995-11-16 AU AU44058/96A patent/AU4405896A/en not_active Abandoned
- 1995-11-16 MX MX9703643A patent/MX9703643A/es unknown
- 1995-11-16 PT PT95942843T patent/PT792287E/pt unknown
- 1995-11-16 EP EP95942843A patent/EP0792287B1/de not_active Expired - Lifetime
- 1995-11-16 CA CA002204147A patent/CA2204147A1/en not_active Abandoned
- 1995-11-16 ES ES95942843T patent/ES2218559T3/es not_active Expired - Lifetime
- 1995-11-16 EP EP03028981A patent/EP1440980A3/de not_active Withdrawn
- 1995-11-16 DK DK95942843T patent/DK0792287T3/da active
- 1995-11-16 JP JP8516911A patent/JPH10509172A/ja active Pending
- 1995-11-16 AT AT95942843T patent/ATE266043T1/de not_active IP Right Cessation
-
1997
- 1997-05-16 NO NO972264A patent/NO972264L/no unknown
-
2001
- 2001-12-11 US US10/015,540 patent/US20020086976A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PT792287E (pt) | 2004-09-30 |
NO972264L (no) | 1997-07-16 |
JPH10509172A (ja) | 1998-09-08 |
US6329499B1 (en) | 2001-12-11 |
AU4405896A (en) | 1996-06-17 |
NO972264D0 (no) | 1997-05-16 |
EP0792287A1 (de) | 1997-09-03 |
EP0792287B1 (de) | 2004-05-06 |
EP1440980A2 (de) | 2004-07-28 |
EP1440980A3 (de) | 2005-01-19 |
DE69532996T2 (de) | 2005-04-14 |
MX9703643A (es) | 1997-08-30 |
ES2218559T3 (es) | 2004-11-16 |
US20020086976A1 (en) | 2002-07-04 |
ATE266043T1 (de) | 2004-05-15 |
WO1996016086A1 (en) | 1996-05-30 |
CA2204147A1 (en) | 1996-05-30 |
DK0792287T3 (da) | 2004-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69532996D1 (de) | Peptidanaloge des menschlichen basischen myelinproteins | |
AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
DE69525544D1 (de) | Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
PT662827E (pt) | Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos | |
RU95115239A (ru) | Аналог эритропоэтина | |
DE69627704D1 (en) | Protegrine | |
AP2000001888A0 (en) | Method for treatment of diabetes using peptides analogues of insulin. | |
PT711305E (pt) | Protegrinas | |
ATE121755T1 (de) | Deletionsanaloga von magaininpeptiden. | |
HUT69169A (en) | T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them | |
GB9606040D0 (en) | Active peptide | |
DK525384D0 (da) | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat | |
HUT58765A (en) | Process for producing peptide compounds and pharmaceutical compositions containing them as active components | |
NZ235497A (en) | Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation | |
DE69636052D1 (de) | Mpl-liganden analoga | |
ATE42308T1 (de) | Pharmakologisch aktive peptide. | |
HUT52117A (en) | Process for producing amblyommin and process for producing pharmaceutical compositions comprising such compound as active ingredient | |
ES2080060T3 (es) | Proteinas que tienen actividad de union a interferon-gamma. | |
HU896448D0 (en) | Process for the preparation of anticoagulant peptides | |
ES2062572T3 (es) | Analogos de somatotropina. | |
DE69418353D1 (de) | Cyclische Pentapeptide mit Beta-Turn und Gamma-Turn | |
ATE27822T1 (de) | Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus. | |
KR950704358A (ko) | 카텝신 l 특이적 저해 폴리펩티드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |